CLINICAL TRAILS CORE
临床试验核心
基本信息
- 批准号:7529388
- 负责人:
- 金额:$ 41.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-06 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:ArtsCancer CenterCancer PatientCitiesClinicalClinical ResearchClinical SciencesClinical TrialsClinical Trials Cooperative GroupCore FacilityEnrollmentGoalsHealthHospitalsInstitutionIrelandMalignant NeoplasmsMissionOhioParticipantPatientsPeer ReviewPharmacologic SubstancePoliciesProceduresProcessProtocols documentationResearchResource SharingSystemTherapeuticTherapeutic StudiesTrainingUniversity Hospitalsanticancer researchauthoritycancer therapydata acquisitionperformance siteprogramsquality assurancetranslational clinical trial
项目摘要
The mission of the Case CCC is to develop and support a highly collaborative and translational clinical trials
program, which is fully integrated and bridges the Case CCC scientific partner institutions at UHC and CCF.
The goal is to provide access for cancer patients residing in northeast Ohio to state-of-the-art clinical trials, to
develop new anticancer therapies, and to contribute to the clinical science of advancing therapeutics for the
cancer patient. The Clinical Trials Shared Resource, also referred to as the Clinical Trials Unit (CTU) core
facility, is responsible for the registration of patients and/or participants and data acquisition for all cancer
protocols, including externally peer reviewed, institutional, pharmaceutical sponsored, and cooperative group
clinical trials at UHC and CCF. The CTU is part of the overall support for clinical trials research and is
coordinated with the PRMS, the DSMP, and is aligned with the priorities of clinical research as outlined by
program and senior leaders. The coordination functions of the CTU have been developed and redeployed to
reflect the coordination of activities supporting clinical trials research at the partner institutions. These
processes were approved after review by the Case CCC EAB. Under the partnership arrangement, two
prominent and clinically active institutions, UHC and CCF, combine efforts in clinical trials cancer research.
The responsibility of the CTU is to coordinate these activities, providing oversight for research staff training,
quality assurance and audit review, developing policy and procedures for clinical trials activation, accrual and
management, and having a procedure for management of disagreements and operational details. Since the
CTU serves as the clinical trials research coordinating center, which is expected to expand to include
oversight to other hospitals that are affiliated with Case (Metro Health and the Cleveland VA), or owned by
the hospital systems of UHC or CCF (a total of 7 other affiliated institutions), the Case CCC needs to have
strong centralized authority. To this end, the CTU is organized to include centralized functions within the
Case CCC and distributed responsibilities that reside within the partnership hospitals, currently the Ireland
Cancer Center of UHC and the Taussig Cancer Center of CCF. In 2005, a total of 3,249 patients were
enrolled onto Case CCC clinical trials, including 877 therapeutic (31% of whom are registered to investigatorinitiated
trials) and 2,366 non-therapeutic studies.
PERFORMANCE SITE(S) (organization, city, state)
University Hospitals of Clevel
案例CCC的使命是开发和支持高度协作和转化的临床试验
该计划是完全整合的,并在UHC和CCF的Case CCC科学合作伙伴机构之间架起了桥梁。
目标是为居住在俄亥俄州东北部的癌症患者提供最先进的临床试验,
开发新的抗癌疗法,并为临床科学做出贡献,
癌症患者。临床试验共享资源,也称为临床试验单元(CTU)核心
该机构负责登记患者和/或参与者以及所有癌症的数据采集
方案,包括外部同行评审、机构、制药赞助和合作小组
UHC和CCF的临床试验。CTU是临床试验研究整体支持的一部分,
与PRMS、DSMP协调,并与以下概述的临床研究优先事项保持一致:
计划和高级领导人。反恐股的协调职能已经发展和重新部署,
反映了合作机构支持临床试验研究活动的协调。这些
经Case CCC EAB审核后,流程获得批准。根据伙伴关系安排,
著名和临床活跃的机构,UHC和CCF,联合收割机在临床试验癌症研究方面的努力。
反恐组的责任是协调这些活动,监督研究人员的培训,
质量保证和审计审查,制定临床试验启动、应计和
管理,并有一个管理分歧和操作细节的程序。以来
CTU作为临床试验研究协调中心,预计将扩大到包括
对其他附属于Case(Metro Health和Cleveland VA)或由
UHC或CCF的医院系统(共7个其他附属机构),案例CCC需要具有
强大的中央集权。为此,反恐组的组织包括中央职能,
案例CCC和合作医院(目前为爱尔兰)内部的分布式责任
UHC癌症中心和CCF Taussig癌症中心。二零零五年,共有3,249名病人
入组病例CCC临床试验,包括877例治疗性(其中31%注册为治疗性启动
试验)和2,366项非治疗性研究。
履约地点(组织、城市、州)
Clevel大学医院
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AFSHIN DOWLATI其他文献
AFSHIN DOWLATI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AFSHIN DOWLATI', 18)}}的其他基金
REBECCAMYCIN AND OXALIPLATIN FOR SOLID TUMORS
瑞贝卡霉素和奥沙利铂治疗实体瘤
- 批准号:
7378058 - 财政年份:2006
- 资助金额:
$ 41.65万 - 项目类别:
REBECCAMYCIN AND OXALIPLATIN FOR SOLID TUMORS
瑞贝卡霉素和奥沙利铂治疗实体瘤
- 批准号:
7202790 - 财政年份:2005
- 资助金额:
$ 41.65万 - 项目类别:
REBECCAMYCIN IN UNRESECTABLE OR METASTATIC HEPATOBILIARY CANCERS
瑞贝卡霉素治疗不可切除或转移性肝胆癌
- 批准号:
7202755 - 财政年份:2005
- 资助金额:
$ 41.65万 - 项目类别:
Rebeccamycin in unresectable or metastatic hepatobiliary cancers
瑞贝卡霉素治疗不可切除或转移性肝胆癌
- 批准号:
6974961 - 财政年份:2004
- 资助金额:
$ 41.65万 - 项目类别:
相似海外基金
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
- 批准号:
10911713 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别:
University of Kansas Cancer Center Midwest Pre-Clinical Imaging Center
堪萨斯大学癌症中心中西部临床前影像中心
- 批准号:
10795272 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别:
Georgetown University Lombardi Comprehensive Cancer Center Support Grant
乔治城大学隆巴迪综合癌症中心支持补助金
- 批准号:
10771760 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别:
UF Health Cancer Center Support Grant - Training Navigator Supplement
佛罗里达大学健康癌症中心支持补助金 - 培训导航补充
- 批准号:
10892335 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别:
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
德克萨斯大学 MD 安德森癌症中心 SPORE 在卵巢癌中的应用
- 批准号:
10709227 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别:
University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical Oncology
堪萨斯大学癌症中心 Paul Calabresi K12 临床肿瘤学职业发展奖
- 批准号:
10647369 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别:
Mayo Comprehensive Cancer Center Grant (MICEO Supp) - Impact of Multi-Channel Communication Campaigns on Cancer Prevention, Control and Survivorship (CaPCaS) in Black, Hispanic, and Rural Populations
梅奥综合癌症中心拨款 (MICEO Supp) - 多渠道沟通活动对黑人、西班牙裔和农村人口癌症预防、控制和生存 (CaPCaS) 的影响
- 批准号:
10889628 - 财政年份:2023
- 资助金额:
$ 41.65万 - 项目类别: